However, pain or discomfort on injection of propofol is a common problem during induction of anesthesia.
The incidence of pain on injection of propofol is reported to vary between 30 and 90% [3] [4] [5] . Furthermore, expert anesthesiologists ranked propofol injection pain during induction as seventh among 33 when both clinical importance and frequency were considered [6] .
The mechanism of propofol injection pain is not fully understood [2, 7] . The chemical mechanisms for propofol injection pain may be the direct irritation via the release of kininogens when propofol contacts with the vascular endothelium [7, 8] , but remain in part unclear. Klement & Arndt supposed that the afferent free nerve endings between the media and intima are the sensors for this pathway [9] . Several methods have been attempted to reduce propofol injection pain, including varying the injection speed and carrier fluid, dilution, cooling or warming the propofol, or concomitant use of drugs [6, 10, 11] . However, these methods have failed to become popular among anesthesiologists because preparations are difficult and they do not completely prevent the injection pain.
The use of opioids such as alfentanil or fentanyl has been found to prevent pain on injection of propofol [12] [13] [14] . Remifentanil is a synthetic, potent and selective μ-opioid receptor agonist with a rapid onset and
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대한치과마취과학회지 제13권 제3호 89-94 ultra-short duration of action [15, 16] . It has also been shown to prevent propofol injection pain in earlier studies [17] [18] [19] .
There are few studies about effect-site target concentration (Ce) of remifentanil at which there is a 50% probability of preventing the propofol pain on injection (Ce50). In the current study, we aimed to evaluate the Ce50 of remifentanil to prevent the pain response associated with propofol injection in adult population. 
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Remifentanil has an analgesic potency 20-30 times of alfentanil and a rapid onset time. The use of remifentanil to prevent the pain of propofol injection has been studied by several investigators [18, 19] . Remifentanil is an opioid of the phenylpiperidine group and could have a local anesthetic effect on nerves. Opioid receptors are found in the dorsal root ganglia, the central terminals of primary afferent nerves and peripheral sensory nerve fibres and their terminals. To have interaction with peripheral opioid receptors, opioids must remain in the body for a certain period of time. Roehm et al [18] . reported this period for remifentanil infusion to be 60 sec in the prevention of propofol-induced injection pain. In this study, remifentanil was administered over 90 sec with a TCI pump on running fluid without the venous occlusion technique; thus, the peripheral effect of remifentanil is less likely.
Regarding the dose of remifentanil, Roehm and colleagues [18] showed that remifentanil 0.25 μg/kg/min before propofol injection is as effective as lidocaine 40 mg prior to propofol injection in reducing the incidence of injection pain (30.2 vs. 62% for placebo). Basaranoglu and colleagues [19] used remifentanil 1 μg/kg/min before propofol, and the incidence of propofol injection pain decreased from 32% to 44%. Considering these result, a dose-dependent effect of remifentanil in attenuating propofol injection pain is suspected. Regardless of the mechanism, it is likely that pretreatment with remifentanil has resulted in a deeper level of anesthesia that increases the pain threshold and thus explains the decreased incidence of propofol injection pain. Further research to find out the optimal bolus dose of remifentanil required for the prevention of withdrawal movement with better hemodynamic stability, is needed.
As compared with these previous studies, we tried to maintain a relatively low target effect-site concentration of propofol to minimize hemodynamic instability [24, 25] .
The pharmacokinetics and pharmacodynamics of remifentanil are known to be influenced by patient age. We delivered remifentanil with effect-site TCI according to the Minto model. Minto et al [20] . In conclusion, the EC50 of remifentanil to prevent the
